Immunocore Holdings (IMCR) reported $400M in revenue for fiscal 2025, +29.0% year on year. That ranks #2348 by revenue among 2853 SEC filers and #229 in Healthcare. It posted a net loss of −$35.5M for the same year. Revenue has grown 82.0% a year on average since 2021 ($36.5M then). The fiscal 2025 balance sheet shows $1.1B in total assets, $468M in cash and $403M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $400M | +29.0% | FY20252025-12-31 |
| Gross profit | Not reported | — | |
| Operating incomeOperatingIncomeLoss | −$45.4M | +$25.1M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$35.5M | +$15.6M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | −$10.7M | −$36.8M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $4.3M | −16.1% | FY20252025-12-31 |
| Total assetsAssets | $1.1B | +5.7% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $381M | +5.6% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $468M | +2.6% | FY20252025-12-31 |
| Long-term debtLongTermDebt | $403M | — | FY20232024-02-02 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $107M | $13.0M | Open → |
| Q2 20262026-06-30 | $116M | −$808,000 | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Immunocore Holdings Plc
- Ticker
- IMCR
- Exchange
- Nasdaq
- SIC classification
- Biological Products, (No Diagnostic Substances) (2836)
- Fiscal year end
- 12-31
- CIK
- 0001671927
Filings
- 10-QAug 6, 2026Open filing →
- 10-QMay 6, 2026Open filing →
- 10-KFeb 25, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Mimedx GroupMDXG | $419M | $48.6M |
| InnovivaINVA | $411M | $271M |
| ArdelyxARDX | $407M | −$62.0M |
| Immunocore HoldingsIMCR | $400M | −$35.5M |
| Krystal BiotechKRYS | $389M | $205M |
| Sinovac BiotechSVA | $386M | −$199M |
| Sonida Senior LivingSNDA | $381M | −$72.5M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Immunocore Holdings — Key figures |url=https://companiesranked.com/en/company/immunocore-holdings |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Immunocore Holdings — Key figures. CompaniesRanked. https://companiesranked.com/en/company/immunocore-holdingsBibTeX
@misc{companiesranked-en-company-immunocore-holdings-2026,
author = {{CompaniesRanked}},
title = {{Immunocore Holdings — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/immunocore-holdings}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001671927-26-000005 · February 25, 2026
{{cite web |title=Immunocore Holdings — Key figures — 10-K (0001671927-26-000005) |url=https://www.sec.gov/Archives/edgar/data/1671927/000167192726000005/imcr-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-25}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.